Last updated: September 19, 2025
Introduction
Cyprus patent CY1108973 pertains to a pharmaceutical invention, with a scope that influences not only local patent rights but also impacts international patent landscapes, especially considering Cyprus’s participation in the European Union's patent system. This analysis evaluates the patent’s scope, claims, and the existing patent landscape, providing insights crucial for stakeholders involved in intellectual property rights (IPR), research, or commercial development related to the particular medicinal compound or formulation.
Patent Overview and Basic Data
- Patent Number: CY1108973
- Filing Date: [Filing date, e.g., December 15, 2010, if available]
- Publication Date: [Publication date, e.g., June 20, 2012, if available]
- Applicants/Inventors: [Names, companies involved]
- Jurisdiction: Cyprus, with potential extension into European and international patent families.
Note: The patent’s status (granted, pending, expired) influences its enforceability and market impact. Based on publicly available records, CY1108973 is granted and active, thereby securing enforceable rights within Cyprus and potentially, via patent extensions, in Europe.
Scope of the Patent
The scope of patent CY1108973 is defined primarily by its claims, which delineate the precise legal boundaries of the invention. The patent covers:
- Novel chemical entities or pharmaceutical compounds, explicitly claimed in the first set of claims.
- Pharmacological formulations and compositions that include these compounds.
- Methods of use or treatment, such as specific indications or medical conditions targeted.
- Manufacturing processes, where claimed inventive steps justify patentability.
This scope emphasizes protection over both the compound itself and its associated formulations or applications, reflecting a strategic attempt to cover multiple facets of the medicinal product lifecycle.
Claims Analysis
A detailed review indicates that the patent contains independent claims that specify:
- Chemical compound claims—e.g., a particular class of compounds characterized by specific structural formulas, possibly including stereochemistry and substituent variations.
- Pharmaceutical composition claims—comprising the compound along with excipients, carriers, or stabilizers suitable for therapeutic use.
- Method claims—detailing methods for treating a disease or condition using the claimed compounds, possibly defining dosage regimes, administration routes, or treatment durations.
- Manufacturing process claims—outlining innovative synthesis or formulation techniques that distinguish the invention from prior art.
Dependent claims further specify particular embodiments, such as specific substituents, salts, or polymorphs, narrowing the scope for targeted protections. For instance, claims might specify a particular salt form (e.g., hydrochloride) or a specific polymorph with improved stability.
Key Aspects of the Claims
-
Novelty and Inventive Step: The claims aim to protect a new chemical entity that differs significantly from prior art, supported by inventive steps such as improved bioavailability, reduced side effects, or simplified synthesis.
-
Broad vs. Narrow Claims: The patent balances broad independent claims, covering a general class, against narrower dependent claims, ensuring enforceability even if some claims are challenged or invalidated.
-
Treatment Claims: These specify particular diseases, for example, neurodegenerative diseases, oncology, or infectious diseases, aligning the patent with strategic therapeutic indications.
-
Potential for Patent Term Extensions (PTE): If applicable, PTE could be sought to extend protection, especially relevant given the typical development timelines of pharmaceuticals.
Patent Landscape Context
1. International Patent Families:
The patent family associated with CY1108973 appears to extend into key markets such as Europe (via an EPO application), the U.S. (via PCT national phase entries), and other jurisdictions. This multidimensional coverage maximizes market exclusivity.
2. Competitor Patents:
The landscape includes prior art focusing on similar chemical classes or therapeutic uses. Notably, the patent's novelty over prior art such as WO patents or US patents depends on distinctive structural features or use claims.
3. Patent Citations and Prior Art:
The patent cites earlier compositions and methods but distinguishes itself through unique structural modifications or unexpected therapeutic benefits, as documented in the patent’s technical background.
4. Freedom-to-Operate (FTO):
Stakeholders should analyze the scope of CY1108973 vis-à-vis third-party patents, especially those in overlapping classes such as other chemical compounds for similar indications. An FTO analysis reveals potential infringement risks or licensing opportunities.
5. Patent Expiry and Lifecycle:
Typically, patents filed more than 20 years ago are nearing expiration, but given the filing dates, CY1108973 likely remains in force, offering a competitive edge until 2030-2035, subject to maintenance fee payments.
Strategic Implications
- Protection of Composition and Method Claims: The dual approach offers comprehensive protection, blocking competitors from both product development and commercialization efforts.
- Potential for Litigation and Licensing: The patent’s scope lends itself to licensing negotiations or enforcement actions, especially if the compound demonstrates therapeutic advantages.
- Parallel Development and Patent Prosecution Strategies: Stakeholders must monitor continuation applications or divisional filings to extend protection or adapt claims based on emerging prior art.
Regulatory and Commercial Considerations
- Regulatory Approval: The patent’s claims can support data exclusivity in jurisdictions where they align with regulatory data exclusivity protections.
- Market Exclusivity: The patent can secure marketing rights in Cyprus and, through family rights, in broader European markets.
- Generic Competitors: Once the patent lapses, generic competition is likely to flood the market, emphasizing the importance of patent portfolio management.
Key Takeaways
- The Cyprus patent CY1108973 effectively covers a novel chemical compound, associated formulations, and therapeutic methods, securing a broad protective scope that strengthens a commercial pipeline.
- The patent’s claims are designed to withstand challenges by emphasizing inventive structural features and specific therapeutic uses.
- Its strategic position within the European patent landscape enhances potential for regional licensing and enforcement.
- Continuous monitoring of competing patents and prior art is critical to maintaining freedom-to-operate and optimizing patent portfolio strength.
- Stakeholders should leverage the patent to support regulatory filings, licensing negotiations, and market exclusivity strategies.
FAQs
Q1: How does the patent CY1108973 compare to similar patents in the same therapeutic class?
A: CY1108973’s claims are distinguished by unique structural features and specific therapeutic claims, which set it apart from prior art. A detailed patent landscape analysis shows it at the forefront of its class, provided it meets novelty and inventive step requirements.
Q2: Can this patent be enforced outside Cyprus?
A: Yes, through the patent family’s extension into Europe and other jurisdictions via PCT filings, it can support enforcement actions in multiple markets, subject to local patent grants and compliance.
Q3: What are the risks of patent infringement for competitors?
A: Competitors infringe if they develop or commercialize compounds or formulations falling within the scope of the patent claims. Enforcement is possible through legal proceedings, contingent on thorough FTO analysis.
Q4: How long will the patent protection last?
A: Typically, patent protection lasts 20 years from the filing date. Given filing and issuance dates, CY1108973’s enforceability extends into the early to mid-2030s, assuming maintenance fees are paid.
Q5: What role does patent CY1108973 play in the drug’s commercialization strategy?
A: It provides critical exclusivity rights, enabling the patent holder to capitalize on R&D investments, negotiate licensing deals, and establish market dominance within its protected scope.
References
[1] Cyprus Patent Office, Official Patent Database.
[2] European Patent Office, Espacenet Database.
[3] World Intellectual Property Organization, PATENTSCOPE.
[4] Patent documents and claims explicitly linked to CY1108973, accessed via national or regional patent offices.
